Brochure
11 Nov 2023
Alteogen signs global licence deal with Sandoz
Sandoz will have global rights to use Alteogen’s ALT-B4 to develop and commercialise a subcutaneous version of a biosimilar product.
Content provided by our supplier
Alteogen
-
KR -
2023On CPHI since
Other Content from Alteogen ()
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance